Tech Company Financing Transactions
aTyr Pharma Funding Round
On 4/1/2015, aTyr Pharma raised $76 million in Series E financing from Sofinnova Ventures, private investors and Deerfield Capital.
Transaction Overview
Company Name
Announced On
4/1/2015
Transaction Type
Venture Equity
Amount
$76,000,000
Round
Series E
Investors
Sofinnova Ventures (Lead Investor) (Srinivas Akkaraju)
private investors (Lead Investor)
Proceeds Purpose
The Company plans to use the proceeds to further develop its pipeline and advance its lead program through clinical trials, including an ongoing Phase 1b/2 trial of Resolaris, an investigational new drug representing aTyr's first Physiocrine-based product candidate in the clinic.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3545 John Hopkins Ct. 250
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
aTyr is leveraging Physiocrine biology, a new and important area of human health, to develop first-in-class medicines to treat patients suffering from severe, rare diseases with significant unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sanjay Shukla
Chief Financial Officer
Jill Broadfoot
VP - General Counsel
Nancy Krueger
VP - Human Resources
Holly Winter
VP - Manufacturing
Andrea Cubitt
Browse more venture capital transactions:
Prev: 4/1/2015: EyeQ venture capital transaction
Next: 4/1/2015: ProsperWorks venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs